Cargando…

A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form

AIMS AND OBJECTIVE: The aim of this study was to develop and validate a novel ultra-performance liquid chromatographic method for estimation of darunavir in a bulk and tablet dosage form. MATERIALS AND METHODS: The chromatographic separation was achieved using DIKMA Endoversil (2.1mm x 50mm, 1.7 µm)...

Descripción completa

Detalles Bibliográficos
Autores principales: Biswal, Sabyasachi, Mondal, Sumanta, Mondal, Prasenjit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142922/
https://www.ncbi.nlm.nih.gov/pubmed/34084050
http://dx.doi.org/10.4103/jpbs.JPBS_337_19
_version_ 1783696648498577408
author Biswal, Sabyasachi
Mondal, Sumanta
Mondal, Prasenjit
author_facet Biswal, Sabyasachi
Mondal, Sumanta
Mondal, Prasenjit
author_sort Biswal, Sabyasachi
collection PubMed
description AIMS AND OBJECTIVE: The aim of this study was to develop and validate a novel ultra-performance liquid chromatographic method for estimation of darunavir in a bulk and tablet dosage form. MATERIALS AND METHODS: The chromatographic separation was achieved using DIKMA Endoversil (2.1mm x 50mm, 1.7 µm) column. A mixture of 40% buffer (0.1% octa sulfonic acid) and 60% acetonitrile was used as a mobile phase with the isocratic elution mode and eluent was monitored at 281nm using UV detector. The method was continued and validated in accordance with International Conference on Harmonization Guidelines. Validation study revealed the specificity and reliability of the method. RESULTS: In this method, darunavir was eluted with retention time of 0.516 min. Calibration curve plots were found linear over the concentration ranges 10–50 μg/mL for darunavir. Limit of detection was 0.02 μg/mL and limit of quantification was found 0.07 μg/mL. The present method was also found stable in force degradation study. CONCLUSION: The empirical evidences of all the study results revealed the suitability of the estimation of darunavir in bulk and tablet dosage form without any interference from the excipients.
format Online
Article
Text
id pubmed-8142922
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-81429222021-06-02 A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form Biswal, Sabyasachi Mondal, Sumanta Mondal, Prasenjit J Pharm Bioallied Sci Original Article AIMS AND OBJECTIVE: The aim of this study was to develop and validate a novel ultra-performance liquid chromatographic method for estimation of darunavir in a bulk and tablet dosage form. MATERIALS AND METHODS: The chromatographic separation was achieved using DIKMA Endoversil (2.1mm x 50mm, 1.7 µm) column. A mixture of 40% buffer (0.1% octa sulfonic acid) and 60% acetonitrile was used as a mobile phase with the isocratic elution mode and eluent was monitored at 281nm using UV detector. The method was continued and validated in accordance with International Conference on Harmonization Guidelines. Validation study revealed the specificity and reliability of the method. RESULTS: In this method, darunavir was eluted with retention time of 0.516 min. Calibration curve plots were found linear over the concentration ranges 10–50 μg/mL for darunavir. Limit of detection was 0.02 μg/mL and limit of quantification was found 0.07 μg/mL. The present method was also found stable in force degradation study. CONCLUSION: The empirical evidences of all the study results revealed the suitability of the estimation of darunavir in bulk and tablet dosage form without any interference from the excipients. Wolters Kluwer - Medknow 2021 2020-12-21 /pmc/articles/PMC8142922/ /pubmed/34084050 http://dx.doi.org/10.4103/jpbs.JPBS_337_19 Text en Copyright: © 2020 Journal of Pharmacy and Bioallied Sciences https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Biswal, Sabyasachi
Mondal, Sumanta
Mondal, Prasenjit
A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form
title A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form
title_full A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form
title_fullStr A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form
title_full_unstemmed A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form
title_short A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form
title_sort novel ultra performance liquid chromatography-pda method development and validation for darunavir in bulk and its application to marketed dosage form
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142922/
https://www.ncbi.nlm.nih.gov/pubmed/34084050
http://dx.doi.org/10.4103/jpbs.JPBS_337_19
work_keys_str_mv AT biswalsabyasachi anovelultraperformanceliquidchromatographypdamethoddevelopmentandvalidationfordarunavirinbulkanditsapplicationtomarketeddosageform
AT mondalsumanta anovelultraperformanceliquidchromatographypdamethoddevelopmentandvalidationfordarunavirinbulkanditsapplicationtomarketeddosageform
AT mondalprasenjit anovelultraperformanceliquidchromatographypdamethoddevelopmentandvalidationfordarunavirinbulkanditsapplicationtomarketeddosageform
AT biswalsabyasachi novelultraperformanceliquidchromatographypdamethoddevelopmentandvalidationfordarunavirinbulkanditsapplicationtomarketeddosageform
AT mondalsumanta novelultraperformanceliquidchromatographypdamethoddevelopmentandvalidationfordarunavirinbulkanditsapplicationtomarketeddosageform
AT mondalprasenjit novelultraperformanceliquidchromatographypdamethoddevelopmentandvalidationfordarunavirinbulkanditsapplicationtomarketeddosageform